APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Based Vaccines for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide-Based Vaccines for Cancer Market Analysis and Forecast 2026-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchPeptide-Based Vaccines for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Based Vaccines for Cancer Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide-Based Vaccines for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Based Vaccines for Cancer Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Based Vaccines for Cancer Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Peptide-Based Vaccines for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide-Based Vaccines for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Peptide-Based Vaccines for Cancer include ACT, Almac, AmbioPharm, Anergis, Immatics, Immatics, Marker Therapeutics, Inc., OncoPep and Sellas Life Sciences, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide-Based Vaccines for Cancer, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide-Based Vaccines for Cancer, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide-Based Vaccines for Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide-Based Vaccines for Cancer sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide-Based Vaccines for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Peptide-Based Vaccines for Cancer sales, projected growth trends, production technology, application and end-user industry.

Peptide-Based Vaccines for Cancer Segment by Company

ACT

Almac

AmbioPharm

Anergis

Immatics

Immatics

Marker Therapeutics, Inc.

OncoPep

Sellas Life Sciences

Ultimovacs

Peptide-Based Vaccines for Cancer Segment by Type

Synthetic Polypeptide Vaccines

Recombinant Polypeptide Vaccine

Other

Peptide-Based Vaccines for Cancer Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Other

Peptide-Based Vaccines for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Based Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Based Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Based Vaccines for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peptide-Based Vaccines for Cancer in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peptide-Based Vaccines for Cancer manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide-Based Vaccines for Cancer sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide-Based Vaccines for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Synthetic Polypeptide Vaccines Major Manufacturers Table 3. Recombinant Polypeptide Vaccine Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Peptide-Based Vaccines for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Infectious Disease Prevention Major Manufacturers Table 7. Cancer Immunotherapy Major Manufacturers Table 8. Other Major Manufacturers Table 9. Peptide-Based Vaccines for Cancer Industry Trends Table 10. Peptide-Based Vaccines for Cancer Industry Drivers Table 11. Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges Table 12. Peptide-Based Vaccines for Cancer Industry Restraints Table 13. Global Peptide-Based Vaccines for Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Peptide-Based Vaccines for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Peptide-Based Vaccines for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2021-2026) Table 17. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2027-2032) Table 18. Global Peptide-Based Vaccines for Cancer Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026) & (K Units) Table 20. Global Peptide-Based Vaccines for Cancer Sales by Region (2027-2032) & (K Units) Table 21. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2021-2026) Table 22. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2027-2032) Table 23. Global Peptide-Based Vaccines for Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Peptide-Based Vaccines for Cancer Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Peptide-Based Vaccines for Cancer Sales Market Share by Manufacturers (2021-2026) Table 27. Global Peptide-Based Vaccines for Cancer Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Peptide-Based Vaccines for Cancer Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Peptide-Based Vaccines for Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Peptide-Based Vaccines for Cancer Manufacturers, Product Type & Application Table 31. Global Peptide-Based Vaccines for Cancer Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Peptide-Based Vaccines for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Peptide-Based Vaccines for Cancer Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2026) Table 38. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2027-2032) Table 39. Global Peptide-Based Vaccines for Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 41. Global Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 42. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2026) Table 43. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2027-2032) Table 44. Global Peptide-Based Vaccines for Cancer Price by Type (2021-2026) & (US$/Unit) Table 45. Global Peptide-Based Vaccines for Cancer Price by Type (2027-2032) & (US$/Unit) Table 46. Global Peptide-Based Vaccines for Cancer Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2026) Table 50. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2027-2032) Table 51. Global Peptide-Based Vaccines for Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 53. Global Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 54. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2026) Table 55. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2027-2032) Table 56. Global Peptide-Based Vaccines for Cancer Price by Application (2021-2026) & (US$/Unit) Table 57. Global Peptide-Based Vaccines for Cancer Price by Application (2027-2032) & (US$/Unit) Table 58. ACT Company Information Table 59. ACT Business Overview Table 60. ACT Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. ACT Peptide-Based Vaccines for Cancer Product Portfolio Table 62. ACT Recent Development Table 63. Almac Company Information Table 64. Almac Business Overview Table 65. Almac Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Almac Peptide-Based Vaccines for Cancer Product Portfolio Table 67. Almac Recent Development Table 68. AmbioPharm Company Information Table 69. AmbioPharm Business Overview Table 70. AmbioPharm Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio Table 72. AmbioPharm Recent Development Table 73. Anergis Company Information Table 74. Anergis Business Overview Table 75. Anergis Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Anergis Peptide-Based Vaccines for Cancer Product Portfolio Table 77. Anergis Recent Development Table 78. Immatics Company Information Table 79. Immatics Business Overview Table 80. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 82. Immatics Recent Development Table 83. Immatics Company Information Table 84. Immatics Business Overview Table 85. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 87. Immatics Recent Development Table 88. Marker Therapeutics, Inc. Company Information Table 89. Marker Therapeutics, Inc. Business Overview Table 90. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio Table 92. Marker Therapeutics, Inc. Recent Development Table 93. OncoPep Company Information Table 94. OncoPep Business Overview Table 95. OncoPep Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. OncoPep Peptide-Based Vaccines for Cancer Product Portfolio Table 97. OncoPep Recent Development Table 98. Sellas Life Sciences Company Information Table 99. Sellas Life Sciences Business Overview Table 100. Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio Table 102. Sellas Life Sciences Recent Development Table 103. Ultimovacs Company Information Table 104. Ultimovacs Business Overview Table 105. Ultimovacs Peptide-Based Vaccines for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio Table 107. Ultimovacs Recent Development Table 108. North America Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 111. North America Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 112. North America Peptide-Based Vaccines for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 113. North America Peptide-Based Vaccines for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 114. North America Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 115. North America Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 116. North America Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 117. North America Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 118. North America Peptide-Based Vaccines for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 119. North America Peptide-Based Vaccines for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 120. North America Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 122. North America Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 123. North America Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 124. North America Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 125. North America Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 126. North America Peptide-Based Vaccines for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 127. North America Peptide-Based Vaccines for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 128. United States Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 129. Canada Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 130. Europe Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 133. Europe Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 134. Europe Peptide-Based Vaccines for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 135. Europe Peptide-Based Vaccines for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 136. Europe Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 139. Europe Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 140. Europe Peptide-Based Vaccines for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 141. Europe Peptide-Based Vaccines for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 142. Europe Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. Europe Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. Europe Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 146. Europe Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 147. Europe Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 148. Europe Peptide-Based Vaccines for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 149. Europe Peptide-Based Vaccines for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 150. Germany Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 151. France Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 152. U.K. Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 153. Italy Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 154. Netherlands Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 155. China Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 156. China Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 157. China Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 158. China Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 159. China Peptide-Based Vaccines for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 160. China Peptide-Based Vaccines for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 161. China Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 162. China Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 163. China Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 164. China Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 165. China Peptide-Based Vaccines for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 166. China Peptide-Based Vaccines for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 167. Asia Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 168. Asia Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 169. Asia Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 170. Asia Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 171. Asia Peptide-Based Vaccines for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 172. Asia Peptide-Based Vaccines for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 173. Asia Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 174. Asia Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 175. Asia Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 176. Asia Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 177. Asia Peptide-Based Vaccines for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 178. Asia Peptide-Based Vaccines for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 179. Asia Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Asia Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Asia Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Asia Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 183. Asia Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 184. Asia Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 185. Asia Peptide-Based Vaccines for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 186. Asia Peptide-Based Vaccines for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 187. Japan Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 188. South Korea Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 189. India Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 190. Australia Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 191. China Taiwan Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 192. Southeast Asia Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 193. SAMEA Peptide-Based Vaccines for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 194. SAMEA Peptide-Based Vaccines for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 195. SAMEA Peptide-Based Vaccines for Cancer Sales by Type (2021-2026) & (K Units) Table 196. SAMEA Peptide-Based Vaccines for Cancer Sales by Type (2027-2032) & (K Units) Table 197. SAMEA Peptide-Based Vaccines for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 198. SAMEA Peptide-Based Vaccines for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 199. SAMEA Peptide-Based Vaccines for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 200. SAMEA Peptide-Based Vaccines for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 201. SAMEA Peptide-Based Vaccines for Cancer Sales by Application (2021-2026) & (K Units) Table 202. SAMEA Peptide-Based Vaccines for Cancer Sales by Application (2027-2032) & (K Units) Table 203. SAMEA Peptide-Based Vaccines for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 204. SAMEA Peptide-Based Vaccines for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 205. SAMEA Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. SAMEA Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. SAMEA Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. SAMEA Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 209. SAMEA Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 210. SAMEA Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 211. SAMEA Peptide-Based Vaccines for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 212. SAMEA Peptide-Based Vaccines for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 213. Brazil Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 214. Argentina Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 215. Chile Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 216. Colombia Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 217. Peru Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 218. Saudi Arabia Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 219. Israel Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 220. UAE Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 221. Turkey Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 222. Iran Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 223. Egypt Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Table 224. Key Raw Materials Table 225. Raw Materials Key Suppliers Table 226. Peptide-Based Vaccines for Cancer Distributors List Table 227. Peptide-Based Vaccines for Cancer Customers List Table 228. Research Programs/Design for This Report Table 229. Authors List of This Report Table 230. Secondary Sources Table 231. Primary Sources List of Figures Figure 1. Peptide-Based Vaccines for Cancer Image Figure 2. Global Peptide-Based Vaccines for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Based Vaccines for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 4. Synthetic Polypeptide Vaccines Image Figure 5. Recombinant Polypeptide Vaccine Image Figure 6. Other Image Figure 7. Global Peptide-Based Vaccines for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Peptide-Based Vaccines for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 9. Infectious Disease Prevention Image Figure 10. Cancer Immunotherapy Image Figure 11. Other Image Figure 12. Global Peptide-Based Vaccines for Cancer Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Peptide-Based Vaccines for Cancer Revenue (2021-2032) & (US$ Million) Figure 14. Global Peptide-Based Vaccines for Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2021-2032) Figure 17. Global Peptide-Based Vaccines for Cancer Sales (2021-2032) & (K Units) Figure 18. Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Peptide-Based Vaccines for Cancer Sales YoY (2021-2032) & (K Units) Figure 21. Europe Peptide-Based Vaccines for Cancer Sales YoY (2021-2032) & (K Units) Figure 22. China Peptide-Based Vaccines for Cancer Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Peptide-Based Vaccines for Cancer Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Peptide-Based Vaccines for Cancer Sales YoY (2021-2032) & (K Units) Figure 25. Global Peptide-Based Vaccines for Cancer Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Peptide-Based Vaccines for Cancer Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Peptide-Based Vaccines for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2032) Figure 31. Global Peptide-Based Vaccines for Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2032) Figure 34. Global Peptide-Based Vaccines for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2032) Figure 37. Global Peptide-Based Vaccines for Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2032) Figure 40. North America Peptide-Based Vaccines for Cancer Revenue Share by Type (2021-2032) Figure 41. North America Peptide-Based Vaccines for Cancer Sales Share by Type (2021-2032) Figure 42. North America Peptide-Based Vaccines for Cancer Revenue Share by Application (2021-2032) Figure 43. North America Peptide-Based Vaccines for Cancer Sales Share by Application (2021-2032) Figure 44. North America Peptide-Based Vaccines for Cancer Revenue Share by Country (2021-2032) Figure 45. North America Peptide-Based Vaccines for Cancer Sales Share by Country (2021-2032) Figure 46. Europe Peptide-Based Vaccines for Cancer Revenue Share by Type (2021-2032) Figure 47. Europe Peptide-Based Vaccines for Cancer Sales Share by Type (2021-2032) Figure 48. Europe Peptide-Based Vaccines for Cancer Revenue Share by Application (2021-2032) Figure 49. Europe Peptide-Based Vaccines for Cancer Sales Share by Application (2021-2032) Figure 50. Europe Peptide-Based Vaccines for Cancer Revenue Share by Country (2021-2032) Figure 51. Europe Peptide-Based Vaccines for Cancer Sales Share by Country (2021-2032) Figure 52. China Peptide-Based Vaccines for Cancer Revenue Share by Type (2021-2032) Figure 53. China Peptide-Based Vaccines for Cancer Sales Share by Type (2021-2032) Figure 54. China Peptide-Based Vaccines for Cancer Revenue Share by Application (2021-2032) Figure 55. China Peptide-Based Vaccines for Cancer Sales Share by Application (2021-2032) Figure 56. Asia Peptide-Based Vaccines for Cancer Revenue Share by Type (2021-2032) Figure 57. Asia Peptide-Based Vaccines for Cancer Sales Share by Type (2021-2032) Figure 58. Asia Peptide-Based Vaccines for Cancer Revenue Share by Application (2021-2032) Figure 59. Asia Peptide-Based Vaccines for Cancer Sales Share by Application (2021-2032) Figure 60. Asia Peptide-Based Vaccines for Cancer Revenue Share by Country (2021-2032) Figure 61. Asia Peptide-Based Vaccines for Cancer Sales Share by Country (2021-2032) Figure 62. SAMEA Peptide-Based Vaccines for Cancer Revenue Share by Type (2021-2032) Figure 63. SAMEA Peptide-Based Vaccines for Cancer Sales Share by Type (2021-2032) Figure 64. SAMEA Peptide-Based Vaccines for Cancer Revenue Share by Application (2021-2032) Figure 65. SAMEA Peptide-Based Vaccines for Cancer Sales Share by Application (2021-2032) Figure 66. SAMEA Peptide-Based Vaccines for Cancer Revenue Share by Country (2021-2032) Figure 67. SAMEA Peptide-Based Vaccines for Cancer Sales Share by Country (2021-2032) Figure 68. Peptide-Based Vaccines for Cancer Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Peptide-Based Vaccines for Cancer Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Synthetic Polypeptide Vaccines
  • Recombinant Polypeptide Vaccine
  • Other
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Other
Companies covered
  • ACT
  • Almac
  • AmbioPharm
  • Anergis
  • Immatics
  • Immatics
  • Marker Therapeutics, Inc.
  • OncoPep
  • Sellas Life Sciences
  • Ultimovacs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide-Based Vaccines for Cancer Market by Type
  3. 1.2.1 Global Peptide-Based Vaccines for Cancer Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Synthetic Polypeptide Vaccines
  5. 1.2.3 Recombinant Polypeptide Vaccine
  6. 1.2.4 Other
  7. 1.3 Peptide-Based Vaccines for Cancer Market by Application
  8. 1.3.1 Global Peptide-Based Vaccines for Cancer Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Infectious Disease Prevention
  10. 1.3.3 Cancer Immunotherapy
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Peptide-Based Vaccines for Cancer Market Dynamics
  1. 2.1 Peptide-Based Vaccines for Cancer Industry Trends
  2. 2.2 Peptide-Based Vaccines for Cancer Industry Drivers
  3. 2.3 Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges
  4. 2.4 Peptide-Based Vaccines for Cancer Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Peptide-Based Vaccines for Cancer Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Peptide-Based Vaccines for Cancer Revenue by Region
  3. 3.2.1 Global Peptide-Based Vaccines for Cancer Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide-Based Vaccines for Cancer Revenue by Region (2021-2026)
  5. 3.2.3 Global Peptide-Based Vaccines for Cancer Revenue by Region (2027-2032)
  6. 3.2.4 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Peptide-Based Vaccines for Cancer Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Peptide-Based Vaccines for Cancer Sales by Region
  9. 3.4.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026)
  11. 3.4.3 Global Peptide-Based Vaccines for Cancer Sales by Region (2027-2032)
  12. 3.4.4 Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Peptide-Based Vaccines for Cancer Revenue by Manufacturers
  2. 4.1.1 Global Peptide-Based Vaccines for Cancer Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Peptide-Based Vaccines for Cancer Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide-Based Vaccines for Cancer Sales by Manufacturers
  6. 4.2.1 Global Peptide-Based Vaccines for Cancer Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Peptide-Based Vaccines for Cancer Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Peptide-Based Vaccines for Cancer Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Peptide-Based Vaccines for Cancer Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Peptide-Based Vaccines for Cancer Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Peptide-Based Vaccines for Cancer Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Peptide-Based Vaccines for Cancer Manufacturers, Product Type & Application
  13. 4.7 Global Peptide-Based Vaccines for Cancer Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Peptide-Based Vaccines for Cancer Market CR5 and HHI
  16. 4.8.2 2025 Peptide-Based Vaccines for Cancer Tier 1, Tier 2, and Tier 3
5 Peptide-Based Vaccines for Cancer Market by Type
  1. 5.1 Global Peptide-Based Vaccines for Cancer Revenue by Type
  2. 5.1.1 Global Peptide-Based Vaccines for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Peptide-Based Vaccines for Cancer Sales by Type
  6. 5.2.1 Global Peptide-Based Vaccines for Cancer Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide-Based Vaccines for Cancer Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Peptide-Based Vaccines for Cancer Sales Market Share by Type (2021-2032)
  9. 5.3 Global Peptide-Based Vaccines for Cancer Price by Type
6 Peptide-Based Vaccines for Cancer Market by Application
  1. 6.1 Global Peptide-Based Vaccines for Cancer Revenue by Application
  2. 6.1.1 Global Peptide-Based Vaccines for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Peptide-Based Vaccines for Cancer Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Peptide-Based Vaccines for Cancer Sales by Application
  6. 6.2.1 Global Peptide-Based Vaccines for Cancer Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Peptide-Based Vaccines for Cancer Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Peptide-Based Vaccines for Cancer Sales Market Share by Application (2021-2032)
  9. 6.3 Global Peptide-Based Vaccines for Cancer Price by Application
7 Company Profiles
  1. 7.1 ACT
  2. 7.1.1 ACT Company Information
  3. 7.1.2 ACT Business Overview
  4. 7.1.3 ACT Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 ACT Peptide-Based Vaccines for Cancer Product Portfolio
  6. 7.1.5 ACT Recent Developments
  7. 7.2 Almac
  8. 7.2.1 Almac Company Information
  9. 7.2.2 Almac Business Overview
  10. 7.2.3 Almac Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Almac Peptide-Based Vaccines for Cancer Product Portfolio
  12. 7.2.5 Almac Recent Developments
  13. 7.3 AmbioPharm
  14. 7.3.1 AmbioPharm Company Information
  15. 7.3.2 AmbioPharm Business Overview
  16. 7.3.3 AmbioPharm Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio
  18. 7.3.5 AmbioPharm Recent Developments
  19. 7.4 Anergis
  20. 7.4.1 Anergis Company Information
  21. 7.4.2 Anergis Business Overview
  22. 7.4.3 Anergis Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Anergis Peptide-Based Vaccines for Cancer Product Portfolio
  24. 7.4.5 Anergis Recent Developments
  25. 7.5 Immatics
  26. 7.5.1 Immatics Company Information
  27. 7.5.2 Immatics Business Overview
  28. 7.5.3 Immatics Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  30. 7.5.5 Immatics Recent Developments
  31. 7.6 Immatics
  32. 7.6.1 Immatics Company Information
  33. 7.6.2 Immatics Business Overview
  34. 7.6.3 Immatics Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  36. 7.6.5 Immatics Recent Developments
  37. 7.7 Marker Therapeutics, Inc.
  38. 7.7.1 Marker Therapeutics, Inc. Company Information
  39. 7.7.2 Marker Therapeutics, Inc. Business Overview
  40. 7.7.3 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio
  42. 7.7.5 Marker Therapeutics, Inc. Recent Developments
  43. 7.8 OncoPep
  44. 7.8.1 OncoPep Company Information
  45. 7.8.2 OncoPep Business Overview
  46. 7.8.3 OncoPep Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 OncoPep Peptide-Based Vaccines for Cancer Product Portfolio
  48. 7.8.5 OncoPep Recent Developments
  49. 7.9 Sellas Life Sciences
  50. 7.9.1 Sellas Life Sciences Company Information
  51. 7.9.2 Sellas Life Sciences Business Overview
  52. 7.9.3 Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio
  54. 7.9.5 Sellas Life Sciences Recent Developments
  55. 7.10 Ultimovacs
  56. 7.10.1 Ultimovacs Company Information
  57. 7.10.2 Ultimovacs Business Overview
  58. 7.10.3 Ultimovacs Peptide-Based Vaccines for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio
  60. 7.10.5 Ultimovacs Recent Developments
8 North America
  1. 8.1 North America Peptide-Based Vaccines for Cancer Market Size by Type
  2. 8.1.1 North America Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
  3. 8.1.2 North America Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
  4. 8.1.3 North America Peptide-Based Vaccines for Cancer Price by Type (2021-2032)
  5. 8.2 North America Peptide-Based Vaccines for Cancer Market Size by Application
  6. 8.2.1 North America Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
  7. 8.2.2 North America Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
  8. 8.2.3 North America Peptide-Based Vaccines for Cancer Price by Application (2021-2032)
  9. 8.3 North America Peptide-Based Vaccines for Cancer Market Size by Country
  10. 8.3.1 North America Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Peptide-Based Vaccines for Cancer Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Peptide-Based Vaccines for Cancer Market Size by Type
  2. 9.1.1 Europe Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
  3. 9.1.2 Europe Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
  4. 9.1.3 Europe Peptide-Based Vaccines for Cancer Price by Type (2021-2032)
  5. 9.2 Europe Peptide-Based Vaccines for Cancer Market Size by Application
  6. 9.2.1 Europe Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
  7. 9.2.2 Europe Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
  8. 9.2.3 Europe Peptide-Based Vaccines for Cancer Price by Application (2021-2032)
  9. 9.3 Europe Peptide-Based Vaccines for Cancer Market Size by Country
  10. 9.3.1 Europe Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Peptide-Based Vaccines for Cancer Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Peptide-Based Vaccines for Cancer Market Size by Type
  2. 10.1.1 China Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
  3. 10.1.2 China Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
  4. 10.1.3 China Peptide-Based Vaccines for Cancer Price by Type (2021-2032)
  5. 10.2 China Peptide-Based Vaccines for Cancer Market Size by Application
  6. 10.2.1 China Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
  7. 10.2.2 China Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
  8. 10.2.3 China Peptide-Based Vaccines for Cancer Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide-Based Vaccines for Cancer Market Size by Type
  2. 11.1.1 Asia Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
  3. 11.1.2 Asia Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
  4. 11.1.3 Asia Peptide-Based Vaccines for Cancer Price by Type (2021-2032)
  5. 11.2 Asia Peptide-Based Vaccines for Cancer Market Size by Application
  6. 11.2.1 Asia Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
  7. 11.2.2 Asia Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
  8. 11.2.3 Asia Peptide-Based Vaccines for Cancer Price by Application (2021-2032)
  9. 11.3 Asia Peptide-Based Vaccines for Cancer Market Size by Country
  10. 11.3.1 Asia Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Peptide-Based Vaccines for Cancer Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide-Based Vaccines for Cancer Market Size by Type
  2. 12.1.1 SAMEA Peptide-Based Vaccines for Cancer Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Peptide-Based Vaccines for Cancer Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Peptide-Based Vaccines for Cancer Price by Type (2021-2032)
  5. 12.2 SAMEA Peptide-Based Vaccines for Cancer Market Size by Application
  6. 12.2.1 SAMEA Peptide-Based Vaccines for Cancer Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Peptide-Based Vaccines for Cancer Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Peptide-Based Vaccines for Cancer Price by Application (2021-2032)
  9. 12.3 SAMEA Peptide-Based Vaccines for Cancer Market Size by Country
  10. 12.3.1 SAMEA Peptide-Based Vaccines for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Peptide-Based Vaccines for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Peptide-Based Vaccines for Cancer Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Peptide-Based Vaccines for Cancer Value Chain Analysis
  2. 13.1.1 Peptide-Based Vaccines for Cancer Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Peptide-Based Vaccines for Cancer Production Mode & Process
  6. 13.2 Peptide-Based Vaccines for Cancer Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Peptide-Based Vaccines for Cancer Distributors
  9. 13.2.3 Peptide-Based Vaccines for Cancer Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst